Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Open Access
- 27 October 2009
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 10 (1) , 99
- https://doi.org/10.1186/1745-6215-10-99
Abstract
With 2.5 million new HIV infections per year, effective preventive methods against HIV are urgently needed, especially in sub-Saharan Africa. MDP301 is an ongoing trial of the vaginal microbicide PRO 2000/5 being conducted by the Microbicides Development Programme. The main objective of the trial is to determine the efficacy and safety of 0.5% and 2% concentrations of PRO 2000/5 gel compared to placebo in preventing vaginally acquired HIV infection.Keywords
This publication has 11 references indexed in Scilit:
- Effectiveness of Cellulose Sulfate Vaginal Gel for the Prevention of HIV Infection: Results of a Phase III Trial in NigeriaPLOS ONE, 2008
- Lack of Effectiveness of Cellulose Sulfate Gel for the Prevention of Vaginal HIV TransmissionNew England Journal of Medicine, 2008
- SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in NigeriaPLOS ONE, 2008
- Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trialThe Lancet, 2007
- Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trialThe Lancet, 2007
- The Potential Impact of Male Circumcision on HIV in Sub-Saharan AfricaPLoS Medicine, 2006
- Overview of effective and promising interventions to prevent HIV infection.2006
- Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trialThe Lancet, 2002
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- Repeated assessment of results in clinical trials of cancer treatmentThe British Journal of Radiology, 1971